Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
Long-Term Survival in GBM: Is It Possible?
Release Date: May-08-09
Credit Expiration Date: May-31-10
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| While the prognosis for newly diagnosed glioblastomas (GBMs) has improved in recent years, the outlook for patients with recurrent GBMs is still dismal. However, the possibility of long-term survival for both types of GBM patients is a hope that may be on the threshold of becoming reality. A growing understanding of the molecular profiles of these tumors and identification of potentially useful target receptors may lead to more effective treatments. This brief program focuses on the recently established standard of care for newly diagnosed GBMs and emerging therapeutic approaches to recurrent tumors. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Andrew B. Lassman, MD
Assistant Professor of Neurology
Memorial Sloan-Kettering Cancer Center
New York, NY
William F. Regine, MD
Professor and Chairman
Department of Radiation Oncology
University of Maryland School of Medicine
Baltimore, MD
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Lassman discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Bristol-Myers Squibb, Cephalon, Eisai, Genentech, and Imclone. He has also received research support from AstraZeneca, Keryx, and Sigma Tau.
Dr. Regine indicates he has no actual or potential conflict of interest to this program. |
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
AKH Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities |
|
|
| |
